Literature DB >> 20310015

Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study.

Takayuki Yamamoto1, Satoru Umegae, Koichi Matsumoto.   

Abstract

BACKGROUND: During active ulcerative colitis (UC), vast numbers of granulocytes, monocytes/macrophages (GM) infiltrate the mucosal tissue and can potentially exacerbate inflammation and injury. Accordingly, we were interested to see if selective depletion of GM by adsorption (GMA) impacts mucosal healing (MH) in UC patients.
METHODS: In all, 124 patients with clinically and endoscopically active UC received 5 or 10 GMA sessions at one or two sessions/week. The endoscopic severity of mucosal inflammation at entry and 1 week after the last GMA session were scored as follows: 0 = normal mucosa and inactive disease; 1 = mild inflammation; 2 = moderate inflammation; 3 = severe inflammation. Likewise, a score 0 or 1 at post-GMA course was defined as MH.
RESULTS: At entry the endoscopic severity of the mucosal inflammation was 2 in 100 patients (81%) and 3 in 24 patients (19%). Following the course of GMA, 56 patients (45%) achieved clinical remission (normal stool frequency and no rectal bleeding). Thirty-four of these 56 responders achieved MH; 32 (94%) of the 34 patients with MH had an endoscopic score of 2 (moderate inflammation) at entry. The maintained clinical remission rate was significantly higher in the 34 patients who achieved MH as compared with 22 patients who achieved clinical remission without MH (P = 0.0005).
CONCLUSIONS: MH is achieved more frequently in patients with moderate than with severe endoscopic severity at entry. Further, patients with MH have a reduced risk of future clinical relapse as compared with patients who achieve remission without MH.

Entities:  

Mesh:

Year:  2010        PMID: 20310015     DOI: 10.1002/ibd.21260

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  24 in total

Review 1.  The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.

Authors:  H Hanai; Y Takeda; M Eberhardson; R Gruber; A R Saniabadi; O Winqvist; R Lofberg
Journal:  Clin Exp Immunol       Date:  2010-11-16       Impact factor: 4.330

Review 2.  "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

Authors:  Cristiano Pagnini; Francesca Menasci; Stefano Festa; Gianenrico Rizzatti; Gianfranco Delle Fave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

Review 3.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice.

Authors:  Kazuhiko Ono; Satoshi Nimura; Yuko Hideshima; Kazuki Nabeshima; Manabu Nakashima
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

5.  Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study.

Authors:  Takayuki Yamamoto; Satoru Umegae; Koichi Matsumoto
Journal:  J Gastroenterol       Date:  2011-06-17       Impact factor: 7.527

6.  Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease.

Authors:  Gerda C Leitner; Nina Worel; Harald Vogelsang
Journal:  Transfus Med Hemother       Date:  2012-07-31       Impact factor: 3.747

7.  The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score.

Authors:  Kentaro Ikeya; Hiroyuki Hanai; Ken Sugimoto; Satoshi Osawa; Shinsuke Kawasaki; Takayuki Iida; Yasuhiko Maruyama; Fumitoshi Watanabe
Journal:  J Crohns Colitis       Date:  2015-11-17       Impact factor: 9.071

8.  Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA.

Authors:  Yoko Yokoyama; Mikio Kawai; Ken Fukunaga; Koji Kamikozuru; Kazuko Nagase; Koji Nogami; Tomoaki Kono; Yoshio Ohda; Masaki Iimuro; Nobuyuki Hida; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto
Journal:  BMC Gastroenterol       Date:  2013-02-12       Impact factor: 3.067

9.  Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be?

Authors:  Maurizio Vecchi; Piero Vernia; Gabriele Riegler; Renata D'Incà; Vito Annese; Siro Bagnoli
Journal:  Clin Exp Gastroenterol       Date:  2013-01-04

Review 10.  Chronic Antibiotic-Refractory Pouchitis: Management Challenges.

Authors:  An Outtier; Marc Ferrante
Journal:  Clin Exp Gastroenterol       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.